ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion

By: PRLog
DALLAS - Nov. 11, 2025 - PRLog -- Cartwheel, a mission-driven company providing innovative first aid solutions for families, has signed a letter of intent (LOI) to license Clearsight Therapeutics' over-the-counter pink eye treatment beginning in 2027. The agreement marks a strategic addition to Cartwheel's expanding portfolio of accessible, family-friendly health products.

"Cartwheel is committed to bringing first aid into the 21st century by offering modern, effective solutions for everyday health challenges," said Joanna Shu, CEO of Cartwheel. "This new addition fits squarely within our mission to support families with products they can trust, and we're thrilled to work with Clearsight Therapeutics to help bring their innovative eye drop to market."

Clearsight Therapeutics was founded by eye care industry veterans to develop better solutions for common eye conditions that impact millions of people each year. Their novel pink eye treatment is designed to be safe, effective, and accessible - aligning closely with Cartwheel's vision for consumer-first care.

"We built Clearsight to reimagine what patient-centric treatment can look like," said Patrick Smale, CEO of Clearsight Therapeutics. "Partnering with Cartwheel ensures this product gets into the hands of the families who need it most. Their team understands the value of innovation, and we're proud to align our mission with theirs."

"The need for accessible, over-the-counter ophthalmic solutions continues to grow," said Jai G. Parekh, MD, MBA, Co-Founder and CEO of EyeCare Consultants of New Jersey and Chief of Cornea at St. Joseph's HealthCare System, NJ. "This partnership between Clearsight and Cartwheel represents a thoughtful, science-backed step toward meeting that demand. It's exciting to see mission-driven companies collaborating to make a real difference in patient care."

The companies will collaborate over the next 12 months to finalize the licensing terms and prepare for regulatory and go-to-market planning, with a commercial launch anticipated in 2027.

About Cartwheel

Cartwheel is an innovative healthcare company transforming the future of first aid with safe, effective, and science-backed solutions. By combining cutting-edge technology with natural alternatives, Cartwheel is reimagining the household medicine cabinet - offering modern treatments for common concerns like lice and pink eye. Learn more at www.gocartwheel.com.

About Clearsight Therapeutics

Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. Learn more at www.clearsighttx.com.

Contact
Media Contact:
Cathy Henry
***@gocartwheel.com

Photos: (Click photo to enlarge)

Cartwheel Logo


Source: Cartwheel

Read Full Story - Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.35
+0.59 (0.26%)
AAPL  273.67
+1.48 (0.54%)
AMD  213.43
+12.37 (6.15%)
BAC  55.27
+1.01 (1.86%)
GOOG  308.61
+4.86 (1.60%)
META  658.77
-5.68 (-0.85%)
MSFT  485.92
+1.94 (0.40%)
NVDA  180.99
+6.85 (3.93%)
ORCL  191.97
+11.94 (6.63%)
TSLA  481.20
-2.17 (-0.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.